Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review

Chin Med J (Engl). 2019 Dec 5;132(23):2856-2864. doi: 10.1097/CM9.0000000000000538.

Abstract

Objective: Adult-onset Still's disease (AOSD) is a rare but clinically well-known polygenic systemic autoinflammatory disease. In this review, we aim to present frontiers in the pathogenesis, clinical features, diagnosis, biomarkers, disease course, prognosis, and treatment in AOSD.

Data sources: We retrieved information from the PubMed database up to July 2019, using various search terms and relevant words, including AOSD and Still's disease.

Study selection: We included data from peer-reviewed journals. Both basic and clinical studies were selected.

Results: Pathogenesis of AOSD involves genetic background, infectious triggers, and immunopathogenesis, mainly the activation of macrophages and neutrophils followed by a cytokine storm. Diagnosis and prognosis evaluation of AOSD is still challenging; therefore, there is an urgent need to identify better biomarkers. Biologic agents, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α antagonists in the treatment of AOSD, have good prospect.

Conclusion: This review highlights the advances in pathogenesis, potential biomarkers, disease course, and treatment in AOSD.

Publication types

  • Review

MeSH terms

  • Biomarkers / metabolism
  • Disease Progression
  • Humans
  • Interleukin-1beta / therapeutic use
  • Interleukin-6 / therapeutic use
  • Still's Disease, Adult-Onset / drug therapy
  • Still's Disease, Adult-Onset / pathology*
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Biomarkers
  • Interleukin-1beta
  • Interleukin-6
  • Tumor Necrosis Factor-alpha